Home Cart Sign in  
Chemical Structure| 28808-62-0 Chemical Structure| 28808-62-0

Structure of Fraxinellone
CAS No.: 28808-62-0

Chemical Structure| 28808-62-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fraxinellone, a natural product isolated and purified from the root barks of Dictamnus dasycarpus Turcz. with neuroprotective, vasorelaxing, insecticidal, and antimicrobial activities, is a selective blocker of voltage-dependent Ca2+ channel, while dictamine relaxed the rat aorta by suppressing the Ca2+ influx through both voltage-dependent and receptor-operated Ca2+ channels, and can dramatically induce apoptosis of activated peripheral CD4(+) T cells in vivo, consequently resulting in less CD4(+) T-cell activation and infiltration to the liver.

Synonyms: Fraxinellone

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fraxinellone

CAS No. :28808-62-0
Formula : C14H16O3
M.W : 232.28
SMILES Code : CC(CCC[C@]1([C@](O2)([H])C3=COC=C3)C)=C1C2=O
Synonyms :
Fraxinellone
MDL No. :MFCD11101451
InChI Key :XYYAFLHHHZVPRN-GXTWGEPZSA-N
Pubchem ID :124039

Safety of Fraxinellone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HT-29 cells 3, 10, 30 μM 24 hours Inhibited TGF-β-induced fibrosis responses by inhibiting the TGF-β/Smad2/3 signaling pathway. Acta Pharmacol Sin. 2023 Dec;44(12):2469-2478
SW480 cells 3, 10, 30 μM 24 hours Inhibited TGF-β-induced fibrosis responses by inhibiting the TGF-β/Smad2/3 signaling pathway. Acta Pharmacol Sin. 2023 Dec;44(12):2469-2478
Human peripheral blood mononuclear cells 40 μM 4 days To evaluate the effect of fraxinellone on human osteoclast differentiation. Results showed that fraxinellone significantly reduced the number of TRAP-positive multinucleated cells and decreased the expression of MMP9, RANK, cathepsin K, integrin β3, and NFATc1. Int J Mol Sci. 2018 Mar 13;19(3):829
Murine bone marrow-derived monocytes 10-40 μM 4 days To evaluate the effect of fraxinellone on osteoclast formation. Results showed that fraxinellone inhibited the formation of TRAP-positive multinucleated cells in a dose-dependent manner and significantly reduced the expression of TRAP, cathepsin K, and MMP9. Int J Mol Sci. 2018 Mar 13;19(3):829
CD19+ B cells 40 μM 4 days To evaluate the effect of fraxinellone on B cell function. Results showed that fraxinellone significantly reduced the expression of AID and Blimp-1 and decreased the production of immunoglobulin G. Int J Mol Sci. 2018 Mar 13;19(3):829
CD4+ T cells 30-50 μM 3 days To evaluate the effect of fraxinellone on Th17 differentiation. Results showed that fraxinellone reduced the proportion of CD4+IL-17+ cells in a dose-dependent manner and significantly decreased the expression of IL-17 and RORγt. Int J Mol Sci. 2018 Mar 13;19(3):829
SCC2095 cells 28.6 μg/ml (IC50) 48 hours Evaluate the anti-proliferation activity of Fraxinellone against oral squamous cell carcinoma cells, showing an IC50 of 28.6 μg/ml, significantly lower than that of ZSP (>500 μg/ml) J Ethnopharmacol. 2015 Aug 22;172:195-201
SH-SY5Y cells ≤1 μM 30 minutes Evaluate the protective effect of Fraxinellone against glutamate toxicity, results showed no significant protection at ≤1 μM ACS Chem Neurosci. 2024 Jul 17;15(14):2612-2622
PC12 cells ≤1 μM 30 minutes Evaluate the protective effect of Fraxinellone against glutamate toxicity, results showed no significant protection at ≤1 μM ACS Chem Neurosci. 2024 Jul 17;15(14):2612-2622
human hypertrophic scar-derived fibroblasts (HSFs) 100 µM, 200 µM, 300 µM 48 hours To evaluate the effect of FRA on the proliferation and migration capacity of HSFs. Results showed that FRA significantly suppressed the proliferation and migration of HSFs. Biol Direct. 2025 Feb 4;20(1):17
human osteosarcoma cell line MG63 0-320μM 0-48 hours FRA inhibited the proliferation and migration of MG63 cells in a dose-dependent manner Front Pharmacol. 2021 Apr 19;12:653212
human osteosarcoma cell line HOS 0-320μM 0-48 hours FRA inhibited the proliferation and migration of HOS cells in a dose-dependent manner Front Pharmacol. 2021 Apr 19;12:653212

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Bile duct ligation (BDL)-induced liver fibrosis Gavage 10, 20, 40 mg/kg Once daily for 4 weeks Fraxinellone significantly ameliorated BDL-induced liver fibrosis, including reduced collagen deposition, serum hyaluronic acid, laminin, and type III procollagen levels, as well as liver hydroxyproline content. Nat Commun. 2016 Nov 17;7:13498
C57BL/6 mice DSS-induced intestinal fibrosis model Intragastric administration 7.5, 15, 30 mg/kg/d Once daily for 45 days Dose-dependently alleviated DSS-induced intestinal impairments and reduced the production of intestinal fibrosis biomarkers. Acta Pharmacol Sin. 2023 Dec;44(12):2469-2478
DBA/1J mice Collagen-induced arthritis (CIA) model Intraperitoneal injection 7.5 mg/kg Three times per week for eight weeks To evaluate the therapeutic effect of fraxinellone on inflammatory arthritis. Results showed that fraxinellone significantly attenuated the clinical and histologic features of arthritis, reduced serum IgG levels, and inhibited the production of TNF-α and IFN-γ. Int J Mol Sci. 2018 Mar 13;19(3):829
New Zealand white rabbits Rabbit ear scar model Subcutaneous injection 100 µM, 300 µM Every other day for 14 days To validate the therapeutic efficacy of FRA on scar formation in vivo. Results showed that FRA significantly attenuated scar formation and improved collagen fiber arrangement. Biol Direct. 2025 Feb 4;20(1):17
Nude mice Osteosarcoma xenograft model Gavage 50 mg/kg and 100 mg/kg Once daily for 21 days FRA treatment inhibited the growth of osteosarcoma, and the pro-apoptotic and autophagy effects of FRA were also proved in vivo Front Pharmacol. 2021 Apr 19;12:653212
Zebrafish Zebrafish larvae Culture medium exposure 10–30 μM 48 hours To evaluate the hepatotoxicity of FRA and its mechanism, the results showed that FRA induces apoptosis by increasing the level of ROS and activating the JNK/P53 pathway, and induces cholestasis by down-regulating bile acid transporters P-gp, Bsep, and Ntcp. Molecules. 2022 Apr 20;27(9):2647

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.31mL

0.86mL

0.43mL

21.53mL

4.31mL

2.15mL

43.05mL

8.61mL

4.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories